Lucy Scientific Discovery, Inc. is an early-stage company, which engages in the manufacture of psychotropics contracts. The company is headquartered in Victoria, British Columbia. The company went IPO on 2023-02-09. The firm is engaged in researching, developing, and manufacturing psychotropic drugs. The firm is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. The company is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The firm is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.

Industry: Pharmaceutical Preparations Peers: Allied Corp.